{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:41:14Z","timestamp":1792687274582,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17777-6","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:27:43Z","timestamp":1758886063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Detection of PEG-specific antibodies in SARS-CoV-2 positive and negative sera with implications for autoimmune reactivity"],"prefix":"10.1038","volume":"15","author":[{"given":"Aristo","family":"Vojdani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elroy","family":"Vojdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"17777_CR1","doi-asserted-by":"crossref","unstructured":"Armstrong, J. K. PEGylated protein drugs: Basic science and clinical applications. In PEGylated Protein Drugs (ed. Veronese, F. M.) 147\u2013168 (Birkh\u00e4user, 2009).","DOI":"10.1007\/978-3-7643-8679-5_9"},{"key":"17777_CR2","doi-asserted-by":"crossref","unstructured":"Zalipsky, S. & Pasut, G. Evolution of polymer conjugation to proteins. In Polymer-Protein Conjugates: from PEGylation and Beyond (eds Pasut, G. & Zalipsky, S.) 3\u201322 (Elsevier, 2020).","DOI":"10.1016\/B978-0-444-64081-9.00001-2"},{"key":"17777_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000233309","volume":"70","author":"AW Richter","year":"1983","unstructured":"Richter, A. W. & Akerblom, E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int. Arch. Allergy Immunol. 70, 124\u2013131 (1983).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"17777_CR4","doi-asserted-by":"crossref","unstructured":"Turecek, P. L. & Siekmann, I. PEG-protein conjugates: nonclinical and clinical toxicity considerations. In Polymer-Protein Conjugates: from PEGylation and Beyond, 61\u2013101 (Elsevier, 2020).","DOI":"10.1016\/B978-0-444-64081-9.00004-8"},{"key":"17777_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.toxlet.2022.01.011","volume":"359","author":"JL Fang","year":"2022","unstructured":"Fang, J. L. et al. Toxicity of high-molecular-weight polyethylene glycols in Sprague Dawley rats. Toxicol. Lett. 359, 22\u201330 (2022).","journal-title":"Toxicol. Lett."},{"key":"17777_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/cncr.22739","volume":"110","author":"JK Armstrong","year":"2007","unstructured":"Armstrong, J. K. et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110, 103\u2013111 (2007).","journal-title":"Cancer"},{"key":"17777_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar4500","volume":"16","author":"MS Hershfield","year":"2014","unstructured":"Hershfield, M. S. et al. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res. Ther. 16, 1\u201311 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"17777_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/wnan.1339","volume":"7","author":"Q Yang","year":"2015","unstructured":"Yang, Q. & Lai, S. K. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscipl. Rev. Nanomed. Nanobiotechnol. 7, 655\u2013677 (2015).","journal-title":"Wiley Interdiscipl. Rev. Nanomed. Nanobiotechnol."},{"key":"17777_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","volume":"244","author":"P Zhang","year":"2016","unstructured":"Zhang, P., Sun, F., Liu, S. & Jiang, S. Anti-PEG antibodies in the clinic: current issues and beyond pegylation. J. Contr. Release. 244, 184\u2013193 (2016).","journal-title":"J. Contr. Release"},{"key":"17777_CR10","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.drudis.2014.08.015","volume":"19","author":"JJF Verhoef","year":"2014","unstructured":"Verhoef, J. J. F., Carpenter, J. F., Anchordoquy, T. J. & Schellekens, H. Potential induction of anti-PEG antibodies and complement activation toward pegylated therapeutics. Drug Discov. Today. 19, 1945\u20131952 (2014).","journal-title":"Drug Discov. Today"},{"key":"17777_CR11","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s11095-016-1961-x","volume":"33","author":"C Lubich","year":"2016","unstructured":"Lubich, C. et al. The mystery of antibodies against polyethylene glycol (PEG)\u2014What do we know? Pharm. Res. 33, 2239\u20132249 (2016).","journal-title":"Pharm. Res."},{"issue":"2","key":"17777_CR12","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaip.2020.09.029","volume":"9","author":"P Sellaturay","year":"2021","unstructured":"Sellaturay, P., Nasser, S. & Ewan, P. Polyethylene glycol-induced systemic allergic reactions (anaphylaxis). J. Aller Clin. Immunol. Pract. 9 (2), 670\u2013675 (2021).","journal-title":"J. Aller Clin. Immunol. Pract."},{"key":"17777_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/cea.13874","volume":"51","author":"P Sellaturay","year":"2021","unstructured":"Sellaturay, P., Nasser, S., Islam, S., Gurugama, P. & Ewan, P. W. Polyethylene glycol is a cause of anaphylaxis to the pfizer\/biontech mRNA COVID-19 vaccine. Clin. Exp. Allergy. 51, 861\u2013863 (2021).","journal-title":"Clin. Exp. Allergy"},{"key":"17777_CR14","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1001\/jama.2021.1967","volume":"325","author":"TT Shimabukuro","year":"2021","unstructured":"Shimabukuro, T. T., Cole, M. & Su, J. R. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the U.S.\u2014December 14, 2020\u2013January 18, 2021. JAMA. 325, 1101\u20131102 (2021).","journal-title":"JAMA"},{"key":"17777_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3390\/vaccines11030613","volume":"11","author":"F Boufidou","year":"2023","unstructured":"Boufidou, F. et al. Anaphylactic reactions to COVID-19 vaccines: an updated assessment based on pharmacovigilance data. Vaccines. 11, 613. https:\/\/doi.org\/10.3390\/vaccines11030613 (2023).","journal-title":"Vaccines"},{"key":"17777_CR16","doi-asserted-by":"publisher","unstructured":"Bent, R. K. et al. PEG allergy\u2014A COVID-19 pandemic-made problem? A German perspective. WAOjournal. 15, 100714. https:\/\/doi.org\/10.1016\/j.waojou.2022.100714 (2022).","DOI":"10.1016\/j.waojou.2022.100714"},{"issue":"11","key":"17777_CR17","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/s41565-021-01001-3","volume":"16","author":"P Bigini","year":"2021","unstructured":"Bigini, P. et al. The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines. Nat. Nanotechnol. 16 (11), 1162\u20131175 (2021).","journal-title":"Nat. Nanotechnol"},{"issue":"4","key":"17777_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.alit.2022.05.007","volume":"71","author":"M Mouri","year":"2022","unstructured":"Mouri, M. et al. Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines. Allergol. Int. 71 (4), 512\u2013519. https:\/\/doi.org\/10.1016\/j.alit.2022.05.007 (2022).","journal-title":"Allergol. Int."},{"key":"17777_CR19","doi-asserted-by":"publisher","first-page":"617089","DOI":"10.3389\/fimmu.2020.617089","volume":"11","author":"A Vojdani","year":"2020","unstructured":"Vojdani, A., Vojdani, E. & Kharrazian, D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front. Immunol. 11, 617089. https:\/\/doi.org\/10.3389\/fimmu.2020.617089 (2020).","journal-title":"Front. Immunol."},{"key":"17777_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41541-023-00766-z","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. Polyethylene glycol (PEG)-associated immune responses trigger clinically relevant lipid nanoparticles in rats. NPJ Vaccines. 8, 169. https:\/\/doi.org\/10.1038\/s41541-023-00766-z (2023).","journal-title":"NPJ Vaccines"},{"key":"17777_CR21","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.1016\/j.vaccine.2022.08.024","volume":"40","author":"JM Carre\u00f1o","year":"2022","unstructured":"Carre\u00f1o, J. M. et al. mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. Vaccine 40, 6114\u20136124 (2022).","journal-title":"Vaccine"},{"key":"17777_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1021\/bc200551b","volume":"23","author":"MR Sherman","year":"2012","unstructured":"Sherman, M. R., Williams, L. D., Sobczyk, M. A., Michaels, S. J. & Saifer, M. G. P. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug. Chem. 23, 485\u2013499 (2012).","journal-title":"Bioconjug. Chem."},{"key":"17777_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jconrel.2022.09.031","volume":"351","author":"M Ibrahim","year":"2022","unstructured":"Ibrahim, M. et al. Polyethylene glycol (PEG): the nature, immunogenicity, and role in the hypersensitivity of pegylated products. J. Contr. Release. 351, 215\u2013230. https:\/\/doi.org\/10.1016\/j.jconrel.2022.09.031 (2022).","journal-title":"J. Contr. Release"},{"key":"17777_CR24","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","volume":"15","author":"BM Chen","year":"2021","unstructured":"Chen, B. M., Cheng, T. L. & Roffler, S. R. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. C S Nano. 15, 14022\u201314048. https:\/\/doi.org\/10.1021\/acsnano.1c05922 (2021).","journal-title":"C S Nano"},{"key":"17777_CR25","doi-asserted-by":"publisher","first-page":"11809","DOI":"10.1021\/acs.analchem.6b03457","volume":"88","author":"Q Yang","year":"2016","unstructured":"Yang, Q. et al. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal. Chem. 88, 11809\u201311812. https:\/\/doi.org\/10.1021\/acs.analchem.6b03457 (2016).","journal-title":"Anal. Chem."},{"key":"17777_CR26","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1016\/S0168-8278(10)60309-1","volume":"52","author":"H Tillmann","year":"2010","unstructured":"Tillmann, H. et al. High prevalence of pre-existing antibodies against polyethylene glycol (PEG) in hepatitis C (HCV) patients which is not associated with impaired response to PEG-interferon. J. Hepatol. 52, S129 (2010).","journal-title":"J. Hepatol."},{"key":"17777_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000233512","volume":"74","author":"AW Richter","year":"1984","unstructured":"Richter, A. W. & Akerblom, E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int. Arch. Allergy Immunol. 74, 36\u201339 (1984).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"17777_CR28","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","volume":"137","author":"NJ Ganson","year":"2016","unstructured":"Ganson, N. J. et al. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a pegylated RNA aptamer. J. Allergy Clin. Immunol. 137, 1610\u20131617 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"17777_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/1756285616633967","volume":"9","author":"JT White","year":"2016","unstructured":"White, J. T. et al. Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial. Ther. Adv. Neurol. Disord. 9, 239\u2013249 (2016).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"17777_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.molimm.2013.07.014","volume":"57","author":"MG Saifer","year":"2014","unstructured":"Saifer, M. G., Williams, L. D., Sobczyk, M. A., Michaels, S. J. & Sherman, M. R. Selectivity of binding of pegs and PEG-like oligomers to anti-PEGantibodies induced by methoxyPEG-proteins. Mol. Immunol. 57, 236\u2013246 (2014).","journal-title":"Mol. Immunol."},{"key":"17777_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41577-022-00825-x","volume":"23","author":"Y Ju","year":"2023","unstructured":"Ju, Y. et al. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat. Rev. Immunol. 23, 135\u2013136 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"17777_CR32","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","volume":"16","author":"Y Ju","year":"2022","unstructured":"Ju, Y. et al. Anti-PEG antibodies boosted by SARS-CoV-2 lipid nanoparticles in mRNA vaccines. ACS Nano. 16, 11769\u201311780. https:\/\/doi.org\/10.1021\/acsnano.2c04543 (2022).","journal-title":"ACS Nano"},{"key":"17777_CR33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jconrel.2022.12.039","volume":"354","author":"Y Bavli","year":"2023","unstructured":"Bavli, Y. et al. Anti-PEG antibodies before and after a first dose of Comirnaty\u00ae (mRNA-LNP-based SARS-CoV-2 vaccine). J. Contr Release. 354, 316\u2013322. https:\/\/doi.org\/10.1016\/j.jconrel.2022.12.039 (2023).","journal-title":"J. Contr Release"},{"key":"17777_CR34","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1039\/d3NH00198a","volume":"8","author":"MFS Deuker","year":"2023","unstructured":"Deuker, M. F. S., Mail\u00e4nder, V., Morsbach, S. & Landfester, K. Anti-PEG antibodies enriched in the protein Corona of pegylated nanocarriers impact the cell uptake. Nanoscale Horiz. 8, 1377\u20131385. https:\/\/doi.org\/10.1039\/d3NH00198a (2023).","journal-title":"Nanoscale Horiz"},{"key":"17777_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/microorganisms12010138","volume":"12","author":"H Zhou","year":"2024","unstructured":"Zhou, H. et al. Polyethylene terephthalate hydrolases in human gut microbiota and their implications for human health. Microorganisms. 12, 138. https:\/\/doi.org\/10.3390\/microorganisms12010138 (2024).","journal-title":"Microorganisms"},{"key":"17777_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrm2330","volume":"9","author":"G van Meer","year":"2008","unstructured":"van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell. Biol. 9, 112\u2013124 (2008).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"17777_CR37","doi-asserted-by":"publisher","first-page":"11199","DOI":"10.1021\/acs.jpclett1c03109","volume":"12","author":"M Paloncyova","year":"2021","unstructured":"Paloncyova, M., Cechova, P., Srejber, M., K\u00fchrov\u00e1, P. & Otyepka, M. I. Role of ionizable lipids in SARS-CoV-2 vaccines as revealed by molecular dynamics simulations: from membrane structure to interaction with mRNA fragments. J. Phys. Chem. Lett. 12, 11199\u201311205. https:\/\/doi.org\/10.1021\/acs.jpclett1c03109 (2021).","journal-title":"J. Phys. Chem. Lett."},{"key":"17777_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.it.2004.02.004","volume":"25","author":"AL Notkins","year":"2004","unstructured":"Notkins, A. L. Polyreactivity of antibody molecules. Trends Immunol. 25, 174\u2013179. https:\/\/doi.org\/10.1016\/j.it.2004.02.004 (2004).","journal-title":"Trends Immunol."},{"key":"17777_CR39","doi-asserted-by":"publisher","first-page":"993","DOI":"10.4049\/jimmunol.1300880","volume":"191","author":"ID Dimitrov","year":"2013","unstructured":"Dimitrov, I. D. et al. Antibody polyreactivity in health and disease: Statu variabilis. J. Immunol. 191, 993\u2013999. https:\/\/doi.org\/10.4049\/jimmunol.1300880 (2013).","journal-title":"J. Immunol."},{"key":"17777_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jaut.2007.07.015","volume":"29","author":"ZH Zhou","year":"2007","unstructured":"Zhou, Z. H., Tzioufas, A. G. & Notkins, A. L. Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J. Autoimmun. 29, 219\u2013228. https:\/\/doi.org\/10.1016\/j.jaut.2007.07.015 (2007).","journal-title":"J. Autoimmun."},{"key":"17777_CR41","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.4049\/jimmunol.1302143","volume":"194","author":"T Khan","year":"2014","unstructured":"Khan, T. & Salunke, D. M. Adjustable locks and flexible keys: plasticity of epitope-paratope interactions in germline antibodies. J. Immunol. 194, 5398\u20135405. https:\/\/doi.org\/10.4049\/jimmunol.1302143 (2014).","journal-title":"J. Immunol."},{"key":"17777_CR42","doi-asserted-by":"publisher","first-page":"1266668","DOI":"10.3389\/fimmu.2023.1266668","volume":"14","author":"M Lecerf","year":"2023","unstructured":"Lecerf, M., Lacombe, R. V. & Dimitrov, J. D. Polyreactivity of antibodies from different B-cell populations is determined by distinct sequence patterns of variable regions. Front. Immunol. 14, 1266668. https:\/\/doi.org\/10.3389\/fimmu.2023.1266668 (2023).","journal-title":"Front. Immunol."},{"key":"17777_CR43","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/nm1101-1189","volume":"7","author":"LA DeGiorgio","year":"2001","unstructured":"DeGiorgio, L. A. et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7, 1189\u20131193 (2001).","journal-title":"Nat. Med."},{"key":"17777_CR44","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/art.20862","volume":"52","author":"Z Zhao","year":"2005","unstructured":"Zhao, Z. et al. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheumatol. 52, 522\u2013530 (2005).","journal-title":"Arthritis Rheumatol."},{"key":"17777_CR45","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jaut.2009.03.011","volume":"33","author":"J Zhang","year":"2009","unstructured":"Zhang, J. et al. Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. J. Autoimmun. 33, 270\u2013274 (2009).","journal-title":"J. Autoimmun."},{"key":"17777_CR46","doi-asserted-by":"publisher","unstructured":"Howard, F. H. N. et al. Understanding immune responses to viruses \u2013 do underlying Th1\/Th2 cell biases predict outcome? Viruses. 1943. https:\/\/doi.org\/10.3390\/v14071493 (2022).","DOI":"10.3390\/v14071493"},{"key":"17777_CR47","doi-asserted-by":"publisher","first-page":"706902","DOI":"10.3389\/fgene.2021.706902","volume":"12","author":"AB Pavel","year":"2021","unstructured":"Pavel, A. B. et al. Th1\/Th2 cytokine imbalance is associated with higher COVID-19 risk mortality. Front. Genet. 12, 706902. https:\/\/doi.org\/10.3389\/fgene.2021.706902 (2021).","journal-title":"Front. Genet."},{"key":"17777_CR48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41541-022-004572-2","volume":"7","author":"L Grigoryan","year":"2022","unstructured":"Grigoryan, L. et al. Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice. NPJ. Vaccines. 7, 55. https:\/\/doi.org\/10.1038\/s41541-022-004572-2 (2022).","journal-title":"NPJ. Vaccines"},{"key":"17777_CR49","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1056\/NEJMra2035343","volume":"384","author":"MC Castells","year":"2021","unstructured":"Castells, M. C. & Phillips, E. J. Maintaining safety with SARS-CoV-2 vaccines. N.E.J.M. 384, 643\u2013649 (2021).","journal-title":"N.E.J.M."},{"key":"17777_CR50","doi-asserted-by":"publisher","first-page":"e28538","DOI":"10.1002\/jmv.28538","volume":"95","author":"GC Baiocchi","year":"2023","unstructured":"Baiocchi, G. C. et al. Cross-sectional analysis reveals autoantibody signatures associated with COVID-19 severity. J. Med. Virol. 95, e28538 (2023).","journal-title":"J. Med. Virol."},{"key":"17777_CR51","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/pbc.26200","volume":"64","author":"H Hasan","year":"2017","unstructured":"Hasan, H., Shaikh, O. M., Rassekh, S. R., Howard, A. F. & Goddard, K. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-Asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review. Pediatr. Blood Cancer. 64, 81\u201388 (2017).","journal-title":"Pediatr. Blood Cancer"},{"key":"17777_CR52","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1043454217741868","volume":"35","author":"EK Browne","year":"2018","unstructured":"Browne, E. K. et al. Clinical characteristics of intravenous PEG-Asparaginase hypersensitivity reactions in patients undergoing treatment for acute lymphoblastic leukemia. J. Pediatr. Oncol. Nurs. 35, 103\u2013109 (2018).","journal-title":"J. Pediatr. Oncol. Nurs."},{"key":"17777_CR53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41514-023-00118-0","volume":"9","author":"DLM Fonseca","year":"2023","unstructured":"Fonseca, D. L. M. et al. Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting Cardiolipin and platelet glycoprotein with age: a systems biology approach. NPJ Aging. 9, 21. https:\/\/doi.org\/10.1038\/s41514-023-00118-0 (2023).","journal-title":"NPJ Aging"},{"key":"17777_CR54","doi-asserted-by":"publisher","first-page":"108480","DOI":"10.1016\/j.clim.2020.108480","volume":"217","author":"A Vojdani","year":"2020","unstructured":"Vojdani, A. & Kharrazian, D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin. Immunol. 217, 108480. https:\/\/doi.org\/10.1016\/j.clim.2020.108480 (2020).","journal-title":"Clin. Immunol."},{"key":"17777_CR55","doi-asserted-by":"publisher","first-page":"1003094","DOI":"10.3389\/fimmu.2022.1003094","volume":"13","author":"A Vojdani","year":"2022","unstructured":"Vojdani, A., Vojdani, E., Melgar, A. L. & Redd, J. Reaction of SARS-CoV-2 antibodies with other pathogens, vaccines, and food antigens. Front. Immunol. 13, 1003094. https:\/\/doi.org\/10.3389\/fimmu.2022.1003094 (2022).","journal-title":"Front. Immunol."},{"key":"17777_CR56","doi-asserted-by":"crossref","unstructured":"Vojdani, A., Yaqinuddin, A., Beretta, A., Reche, P. A. Editorial cross-reactive immunity and COVID-19. Front. Immunol. (2024). (Special Issue).","DOI":"10.3389\/fimmu.2024.1509379"},{"key":"17777_CR57","doi-asserted-by":"publisher","first-page":"W431","DOI":"10.1093\/nar\/gkab314","volume":"49","author":"D Sehnal","year":"2021","unstructured":"Sehnal, D. et al. Mol* viewer: modern web app for 3D visualization and analysis of large biomolecular structures. Nucleic Acids Res. 49, W431\u2013W437 (2021).","journal-title":"Nucleic Acids Res."},{"key":"17777_CR58","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1021\/acsbiomaterials.7b00147","volume":"3","author":"J McCallen","year":"2017","unstructured":"McCallen, J., Prybylski, J., Yang, Q. & Lai, S. K. A. C. S. Biomater. Sci. Eng. 3, 1605\u20131615. https:\/\/doi.org\/10.1021\/acsbiomaterials.7b00147 (2017).","journal-title":"Sci. Eng."},{"key":"17777_CR59","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1021\/bc200551b","volume":"23","author":"MR Sherman","year":"2012","unstructured":"Sherman, M. R., Williams, L. D., Sobczyk, M. A., Michaels, S. J. & Saifer, M. G. Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug. Chem. 23, 485\u2013499 (2012).","journal-title":"Bioconjug. Chem."},{"key":"17777_CR60","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","volume":"12","author":"PA Dinndori","year":"2007","unstructured":"Dinndori, P. A., Gootenberg, J., Cohen, M. H., Keegan, P. & Pazdur, R. FDA drug approval summary: Pegaspargase (Oncaspar\u00ae) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 12, 991\u2013998 (2007).","journal-title":"Oncologist"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17777-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:27:47Z","timestamp":1758886067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17777-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17777"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17777-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33184"}}